Nanometer composite emulsion of dihydromyricetin as well as preparation method and application of nanometer composite emulsion

Abstract

The invention belongs to the field of biological agents, and particularly relates to a dihydromyricetin nano-composite emulsion and a preparation method and application thereof.The dihydromyricetin nano-composite emulsion is prepared from, by weight, 0.5%-3.0% of dihydromyricetin, 2.0%-8.0% of a hydrophilic core solvent, 12.5%-25.5% of a lipid carrier of a bidirectional hydrophilic structure and 63.5%-85.0% of an outer water phase, the preparation method comprises the following steps: completely dissolving DHM in a hydrophilic core solvent, wrapping the DHM in a natural or synthetic lipid carrier with a bidirectional hydrophilic structure to form a water-in-oil nano-emulsion, and dispersing the water-in-oil nano-emulsion in an external water phase by utilizing the bidirectional hydrophilicity of the lipid carrier to form a novel composite emulsion with the particle size of 10-500 nanometers. The defects in the prior art are overcome, the solubility of the DHM can be greatly improved, the normal-temperature stability of the DHM is remarkably improved, the DHM lipid particles can reach the nanoscale and are not prone to segregation, the permeability of the DHM is obviously improved, and the bioavailability of the DHM is improved.

Description

Technical Field

[0001] The invention belongs to the field of biological preparations, and specifically relates to a nano composite emulsion of dihydromyricetin and a preparation method and application thereof. Background Art

[0002] Dihydromyricetin (DHM) is a natural dihydroflavonol compound, which is found in high concentrations in the pseudofruit of large-leaved vine and sour jujube. Its molecular formula is C 15 H 12 O8, molecular weight is 320.25g / mol, its molecular structure is shown in Figure 1 DHM has poor chemical stability, mainly because it contains 5 phenolic hydroxyl groups, which are easily oxidized by trace amounts of Fe 3+ , Cu 2+ It can be chemically degraded by metal ions such as ions and photocatalytic oxidation. It can exist relatively stably in a low-temperature weakly acidic environment, but its degree of oxidation will increase with the increase of pH value and temperature. DHM has poor water solubility and fat solubility. Its solubility in water at 25°C is 0.2 mg / mL, and its oil-water (n-octanol-water) partition coefficient is only 0.45. Low water solubility and fat solubility lead to low bioavailability of DHM. Literature reports that the intestinal mucosal permeability of DHM in rats is 9.3×10 -6 cm / s, but there is no report on the bioavailability of DHM in humans. The intestinal mucosal permeability in the human gastrointestinal tract is estimated to be less than 10%. The pharmacokinetic results of DHM show that after oral administration of 100 mg / kg body weight to rats, the peak time of DHM is 32.2 minutes, and the highest concentration in rat plasma is C max It is only about 80ng / mL, the absorption phase half-life is 13.2min, and the elimination phase half-life is 17.9min, indicating that DHM has a short half-life in animals, rapid absorption and metabolism, and very low oral bioavailability.

[0003] Pharmacological studies have shown that DHM has good antioxidant, anti-cancer, anti-inflammatory, anti-microbial, liver protection, lipid and glucose metabolism regulation and other pharmacological activities, and has good safety, which makes it of great development value. The solubility and stability of flavonoids are the key to their bioavailability in the body, but DHM is classified as a Class IV2 compound according to the biopharmaceutical classification standards due to its low solubility and low permeability. In addition, DHM has defects such as poor molecular stability and short half-life, which make its bioavailability low and its drugability poor, limiting its clinical application.

[0004] For Class IV compounds, generally speaking, improving solubility and permeability helps improve their clinical performance. In order to improve the above-mentioned problems of DHM, in recent years, the research on improving the stability, solubility and bioavailability of DHM by adopting various new formulation technologies and new dosage forms has become a hot topic. There have been studies on DHM liposomes, microemulsions, microcapsules, nanomicelles, etc., but none of them have completely solved the problem of significantly improving the solubility and in vitro stability of DHM. According to literature reports, some scholars made DHM into liposomes to improve the stability of DHM, but only increased its solubility from the original 0.2 mg / ml to 1.02 mg / ml, and the solubility increase level was only 5 times. Other scholars made DHM into microemulsions or microcapsules. Although the solubility was effectively improved, the particle size of the droplets in the system was large, all above 1000 nm, which made the droplets easy to aggregate, thereby affecting the stability of DHM in the system. Developing a new emulsion tailored to the characteristics of DHM to solve its problems such as low solubility, low permeability, poor stability, and short half-life, thereby increasing its bioavailability, improving its drugability, and expanding the clinical application prospects of DHM has significant scientific research significance and market value. Summary of the invention

[0005] In view of the above-mentioned characteristics of DHM, the technical problem solved by the present invention is to propose a novel nanocomposite emulsion of dihydromyricetin and a preparation method thereof. DHM is first completely dissolved in a hydrophilic core solvent, and then encapsulated in a natural or synthetic lipid carrier with a bidirectional hydrophilic structure to form an oil-in-water nanoemulsion. The bidirectional hydrophilicity of the lipid carrier is utilized to disperse the oil-in-water nanoemulsion in an external aqueous phase to form a novel composite emulsion with a particle size of 10 to 500 nanometers. The present invention overcomes the defects of the prior art, can greatly improve the solubility of DHM, and significantly increase its room temperature stability. The DHM lipid particles can reach the nanometer level and are not easily segregated, which significantly improves the permeability of DHM and improves its bioavailability.

[0006] The present invention provides a nanocomposite emulsion of dihydromyricetin, which comprises the following components by weight percentage: 0.5-3.0 wt.% of dihydromyricetin, 2.0-8.0 wt.% of a hydrophilic inner core solvent, 12.5-25.5 wt.% of a lipid carrier with a bidirectional hydrophilic structure, 63.5-85.0 wt.% of an outer aqueous phase,

[0007] Preferably, the hydrophilic core solvent includes glycerol, propylene glycol and water;

[0008] Preferably, in terms of weight percentage, the ratio of glycerol to propylene glycol in the hydrophilic core solvent is 0.2 to 1:1;

[0009] Preferably, the glycerol in the hydrophilic core solvent can be replaced by PEG300 or PEG400;

[0010] DHM has poor water solubility and fat solubility, and its solubility in water at 25°C is only 0.2 mg / mL, and its oil-water (n-octanol-water) partition coefficient is only 0.45. According to the principle of like dissolves like, non-aqueous solvents with strong polarity can effectively increase the concentration of DHM in the solution. The present invention optimizes four solvents of glycerol, propylene glycol, PEG300 and PEG 400, and obtains the best ratio between the solvents. However, DHM still has the problem of poor stability in polar non-aqueous solvents. In order to increase the stability of the product, DHM needs to be prepared into a composite nanoemulsion.

[0011] Preferably, the bi-directional hydrophilic lipid carrier comprises a water-in-oil emulsifier, an emulsifier aid and oil;

[0012] Preferably, the water-in-oil emulsifier is any one of triglycerol dioleate, sorbitan monostearate, and sorbitan monooleate;

[0013] Preferably, the co-emulsifier is any one of natural or synthetic soybean lecithin, natural or synthetic egg yolk lecithin;

[0014] Preferably, the oil comprises any one of natural or purified coconut oil, natural or synthetic medium-chain triglyceride fatty acid ester, olive oil, avocado oil, or soybean oil;

[0015] Preferably, in terms of weight percentage, the content of the water-in-oil emulsifier in the bi-directional hydrophilic lipid carrier is 2.5wt.% to 4wt.%, the content of the auxiliary emulsifier is 1.5wt.% to 2.5wt.%, and the content of the oil is 3.4wt.% to 7.6wt.%;

[0016] The bi-directional hydrophilic lipid carrier has a protective effect on the stability of DHM in the hydrophilic core, and can prevent DHM from being oxidized and precipitating from the solution due to environmental changes. At this stage, the bi-directional hydrophilic lipid carrier is the external phase, and the hydrophilic core is the internal water phase. The lipid carrier contains an oil phase, and an oil-in-water emulsifier is used to stabilize the internal phase. Lecithin is used as an emulsifier to maintain affinity for the internal water phase.

[0017] Preferably, the external aqueous phase comprises an oil-in-water emulsifier, calcium disodium ethylenediaminetetraacetic acid, vitamin C, an antibacterial agent, and water;

[0018] Preferably, the oil-in-water emulsifier is any one of Tween 80, vitamin E derivatives, lauroyl macrogol glyceride or polyoxyethylene hydrogenated castor oil derivatives;

[0019] Preferably, the vitamin E derivative is vitamin E polyethylene glycol succinate;

[0020] Preferably, the antibacterial agent is any one of sodium benzoate or potassium sorbate;

[0021] Preferably, in terms of weight percentage, the content of the water-in-oil emulsifier in the external aqueous phase is 4-6wt.%, the content of calcium disodium ethylenediaminetetraacetic acid is not more than 0.0025wt.%, the content of vitamin C is 0.1wt.%-0.5wt.%, and the content of the antibacterial agent is not more than 0.1wt.%;

[0022] The main function of the external water phase is to increase the compatibility of the product with other hydrophilic solutions and meet the needs of consumers for taste adjustment. The external water phase is added with an oil-in-water emulsifier to increase the affinity with lipid carriers. The chelating agent calcium disodium ethylenediaminetetraacetic acid prevents metal ions from oxidizing the product. Vitamin C, as an antioxidant, can consume oxygen in the product and reduce the oxidation of DHM. The antibacterial agent can inhibit the growth of bacteria and ensure the safety of the product.

[0023] The present invention provides a method for preparing a nanocomposite emulsion of dihydromyricetin, comprising the following steps:

[0024] S1: Accurately weigh the material components of dihydromyricetin and hydrophilic core solvent according to weight percentage, first place the components of the hydrophilic core solvent in an appropriate container, stir and mix evenly, and heat the solvent to 50-60° C. in a water bath environment to obtain a hydrophilic core solvent, then pass the solid powder of dihydromyricetin through a 40-mesh sieve, and slowly sieve it into the hydrophilic core solvent being stirred to fully dissolve it, so as to prepare a dihydromyricetin-hydrophilic core solution;

[0025] S2: Accurately weigh the water-in-oil emulsifier, the co-emulsifier and the oil according to the weight percentage, mix the three materials in a suitable container, and heat them to 50-60° C. in a water bath environment. After they are fully melted, continue to stir them thoroughly to mix the solution evenly, so as to obtain a lipid carrier with a bidirectional hydrophilic structure;

[0026] S3: adding the dihydromyricetin-hydrophilic core solution prepared in step S1 to the lipid carrier solution with a bidirectional hydrophilic structure prepared in step S2 at a rate of 1 drop / s, and magnetically stirring the mixed solution while adding, and continuing to magnetically stir for 30 minutes after the addition is completed, and then ultrasonically treating the mixed solution to obtain an oil-in-water nanoemulsion,

[0027] S4: Accurately weigh the materials of the external aqueous phase according to the weight percentage, add the water-in-oil emulsifier, calcium disodium ethylenediaminetetraacetic acid, vitamin C and antibacterial agent to water, heat to 50-60° C., and stir thoroughly to dissolve to obtain the external aqueous phase;

[0028] S5: stirring the water-in-oil nanoemulsion prepared in step S3, and slowly adding the external water phase prepared in step S4 while stirring, and performing ultrasonic treatment again, to finally prepare a dihydromyricetin nanocomposite emulsion.

[0029] Preferably, the ultrasonic treatment in step S3 and step S5 is: in an ice bath, ultrasonic treatment is performed for 5 minutes each time, with an interval of 2 minutes each time, and repeated 3 times, the ultrasonic power is 500W, and the ultrasonic amplitude is 80%;

[0030] Preferably, the ultrasonic treatment in step S3 and step S5 can also be replaced by a homogenization treatment, wherein the mixed solution is placed in a homogenizer for homogenization, the power of the homogenizer is 200W, the temperature is controlled at 50-60°C, 2min / time, 3min interval each time, and repeated 6 times.

[0031] The present invention provides use of a nano-composite emulsion of dihydromyricetin in medicines, health products or health drinks. The medicines include one or more of the medicines for anti-oxidation, anti-cancer, anti-inflammatory, anti-microbial, liver protection and hangover relief.

[0032] Compared with the prior art, the present invention has the following beneficial effects:

[0033] (1) The solubility of DHM was significantly improved, and the solubility of DHM was increased by at least 100 times, from 0.2 mg / ml to at least 20 mg / ml;

[0034] (2) Significantly improved the stability of DHM: the stability of DHM at room temperature can reach 12 months, ensuring

[0035] The medicines and health products prepared with it have a good shelf life, making the clinical administration of DHM possible;

[0037] (3) Significantly improved the permeability of DHM: the lipid particles of DHM reached the nanometer level of 10-500 nanometers.

[0038] It is easy to aggregate and more stable; when the lipid particles decrease from 200 microns to 200 nanometers, the ratio of the particles

[0039] The surface area increased by more than 1000 times, which improved the affinity and penetration of DHM on the gastrointestinal mucosal surface.

[0040] permeability, thereby improving the oral bioavailability of DHM, and promoting the development of DHM in antioxidant,

[0041] It has clinical applications in a variety of pharmacological activities such as anti-cancer, anti-inflammatory, anti-microbial, and liver protection. BRIEF DESCRIPTION OF THE DRAWINGS

[0042] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.

[0043] Figure 1 This is the molecular structure diagram of dihydromyricetin;

[0044] Figure 2 The figure is a schematic diagram of the preparation process of the dihydromyricetin nanocomposite emulsion disclosed in the present invention;

[0045] Figure 3 This is a particle size analysis graph of the sample prepared in Example 1;

[0046] Figure 4 This is a particle size analysis graph of the sample prepared in Example 2;

[0047] Figure 5 This is a particle size analysis graph of the sample prepared in Example 3;

[0048] Figure 6 Chromatogram of the sample prepared in Example 1;

[0049] Figure 7 The macroscopic morphology of the samples prepared in Examples 1 to 3; DETAILED DESCRIPTION

[0050] The following examples are used to illustrate the present invention, but are not intended to limit the scope of the present invention. Without departing from the spirit and essence of the present invention, modifications or substitutions made to the methods, steps or conditions of the present invention are within the scope of the present invention. Unless otherwise specified, the chemical reagents used in the examples are conventional commercial reagents, and the technical means used in the examples are those skilled in the art.

[0051] The specific implementation of the present invention is as follows:

[0052] A method for preparing a nanocomposite emulsion of dihydromyricetin comprises the following steps:

[0053] S1: Accurately weigh the material components of dihydromyricetin and hydrophilic core solvent according to weight percentage, first place the components of the hydrophilic core solvent in an appropriate container, stir and mix evenly, and heat the solvent to 50-60° C. in a water bath environment to obtain a hydrophilic core solvent, then pass the solid powder of dihydromyricetin through a 40-mesh sieve, and slowly sieve it into the hydrophilic core solvent being stirred to fully dissolve it, so as to prepare a dihydromyricetin-hydrophilic core solution;

[0054] S2: Accurately weigh the water-in-oil emulsifier, the co-emulsifier and the oil according to the weight percentage, mix the three materials in a suitable container, and heat them to 50-60° C. in a water bath environment. After they are fully melted, continue to stir them thoroughly to mix the solution evenly, so as to obtain a lipid carrier with a bidirectional hydrophilic structure;

[0055] S3: adding the dihydromyricetin-hydrophilic core solution prepared in step S1 to the lipid carrier solution with a bidirectional hydrophilic structure prepared in step S2 at a rate of 1 drop / s, and magnetically stirring the mixed solution while adding, and continuing to magnetically stir for 30 minutes after the addition is completed, and then ultrasonically treating or homogenizing the mixed solution to obtain a water-in-oil nanoemulsion,

[0056] S4: Accurately weigh the materials of the external aqueous phase according to the weight percentage, add the water-in-oil emulsifier, calcium disodium ethylenediaminetetraacetic acid, vitamin C and antibacterial agent to water, heat to 50-60° C., and stir thoroughly to dissolve to obtain the external aqueous phase;

[0057] S5: stirring the water-in-oil nanoemulsion prepared in step S3, and slowly adding the external water phase prepared in step S4 while stirring, and performing ultrasonic treatment or homogenization treatment again, to finally prepare a dihydromyricetin nanocomposite emulsion.

[0058] The ultrasonic treatment in step S3 and step S5 is as follows: in an ice bath, ultrasonic treatment is performed for 5 minutes each time, with an interval of 2 minutes each time, and repeated 3 times, the ultrasonic power is 500W, and the ultrasonic amplitude is 80%;

[0059] The ultrasonic treatment in step S3 and step S5 can also be replaced by a homogenization treatment, wherein the mixed solution is placed in a homogenizer for homogenization, the power of the homogenizer is 200W, the temperature is controlled at 50-60°C, 2min / time, 3min interval each time, and repeated 6 times.

[0060] Example 1

[0061] Example 1 was prepared according to the above specific implementation method. Table 1 shows the material components and preparation methods involved in Example 1.

[0062] Table 1 Material components and preparation methods involved in Example 1

[0063]

[0064]

[0065] Example 2

[0066] Example 2 was prepared according to the above specific implementation method. Table 2 shows the material components and preparation methods involved in Example 2.

[0067] Table 2 Material components and preparation methods involved in Example 2

[0068]

[0069] Example 3

[0070] Example 3 was prepared according to the above specific implementation method. Table 3 shows the material components and preparation methods involved in Example 2.

[0071] Table 3 Material components and preparation methods involved in Example 3

[0072]

[0073]

[0074] Comparative Example 1

[0075] Comparative Example 1 was prepared according to the above specific implementation method. Table 4 shows the material components and preparation methods involved in Comparative Example 1.

[0076] Table 4 Material components and preparation methods involved in Comparative Example 1

[0077]

[0078] Comparative Example 2

[0079] Comparative Example 2 was prepared according to the above specific implementation method. Table 5 shows the material components and preparation methods involved in Comparative Example 1.

[0080] Table 5 Material components and preparation methods involved in Comparative Example 2

[0081]

[0082]

[0083] Comparative Example 3

[0084] Comparative Example 3 was prepared according to the above specific implementation method. Table 6 shows the material components and preparation methods involved in Comparative Example 3.

[0085] Table 6 Material components and preparation methods involved in Comparative Example 3

[0086]

[0087] Comparative Example 4

[0088] Comparative Example 4 was prepared according to the above specific implementation method. Table 7 shows the material components and preparation methods involved in Comparative Example 4.

[0089] Table 7 Material components and preparation methods involved in Comparative Example 4

[0090]

[0091] Comparative Example 5

[0092] Comparative Example 5 was prepared according to the above specific implementation method. Table 8 shows the material components and preparation methods involved in Comparative Example 5.

[0093] Table 8 Material components and preparation methods involved in Comparative Example 5

[0094]

[0095] According to the commonly used quality evaluation method for nanoemulsions, the dihydromyricetin nanocomposite emulsions prepared in Examples 1 to 3 and Comparative Examples 1 to 5 were subjected to relevant performance tests. The test results are shown in Table 9.

[0096] Table 9 Performance test results of nanocomposite emulsions prepared in Examples and Comparative Examples

[0097]

[0098] As can be seen from Table 9, the DHM content of the DHM nanocomposite emulsion prepared in the embodiment of the present invention can reach up to 3wt.%, and the stability of DHM at room temperature and low temperature can exceed 4 months, and the DHM content is not lost, and the average size of the lipid particles can reach a minimum of 80nm, showing good comprehensive performance; while the nanocomposite emulsions prepared in Comparative Examples 1 to 3 have a lower DHM content, and the DHM content is lost during storage at room temperature and low temperature, and its stability is lacking, and the average size of the lipid particles is relatively large; the nanocomposite emulsions prepared in Comparative Examples 4 and 5 have poor stability, and significant white precipitation occurs after one week at room temperature and 3 days at low temperature.

[0099] Although the present invention has been described in detail above with general descriptions and specific embodiments, it is obvious to those skilled in the art that some modifications or improvements may be made thereto based on the present invention. Therefore, these modifications or improvements made without departing from the spirit of the present invention all fall within the scope of protection claimed by the present invention.

Claims

1. A nanocomposite emulsion of dihydromyricetin, characterized in that: In terms of weight percentage, it includes the following components: 0.5-3.0wt.% dihydromyricetin, 2.0-8.0wt.% hydrophilic inner core solvent, 12.5-25.5wt.% lipid carrier with bi-directional hydrophilic structure, and 63.5-85.0wt.% external water phase.

2. The nanocomposite emulsion of dihydromyricetin according to claim 1, characterized in that: The hydrophilic core solvent includes glycerol, propylene glycol and water. In terms of weight percentage, the glycerol:propylene glycol in the hydrophilic core solvent is 0.2 to 1:

1. The glycerol in the hydrophilic core solvent can be replaced by PEG300 or PEG400.

3. The nanocomposite emulsion of dihydromyricetin according to claim 1, characterized in that: The lipid carrier with a bidirectional hydrophilic structure includes a water-in-oil emulsifier, an auxiliary emulsifier and oil.

4. The nanocomposite emulsion of dihydromyricetin according to claim 4, characterized in that: The water-in-oil emulsifier is any one of triglycerol dioleate, sorbitan monostearate, and sorbitan monooleate; the co-emulsifier is any one of natural or synthetic soybean lecithin and natural or synthetic egg yolk lecithin; the oil includes any one of natural or purified coconut oil, natural or synthetic medium-chain triglyceride fatty acid ester, olive oil, avocado oil, or soybean oil.

5. The nanocomposite emulsion of dihydromyricetin according to claim 4, characterized in that: In terms of weight percentage, the content of water-in-oil emulsifier in the bi-directionally hydrophilic lipid carrier is 2.5wt.% to 4wt.%, the content of auxiliary emulsifier is 1.5wt.% to 2.5wt.%, and the content of oil is 3.4wt.% to 7.6wt.%.

6. The nanocomposite emulsion of dihydromyricetin according to claim 1, characterized in that: The external water phase comprises an oil-in-water emulsifier, calcium disodium ethylenediaminetetraacetic acid, vitamin C, an antibacterial agent and water.

7. The nanocomposite emulsion of dihydromyricetin according to claim 7, characterized in that: The water-in-oil emulsifier is any one of Tween 80, vitamin E derivatives, lauroyl macrogol glyceride or polyoxyethylene hydrogenated castor oil derivatives; the vitamin E derivative is vitamin E macrogol succinate; and the antibacterial agent is any one of sodium benzoate or potassium sorbate.

8. The nanocomposite emulsion of dihydromyricetin according to claim 7, characterized in that: In terms of weight percentage, the content of the water-in-oil emulsifier in the external aqueous phase is 4-6wt.%, the content of calcium disodium ethylenediaminetetraacetic acid is not more than 0.0025wt.%, the content of vitamin C is 0.1wt.%-0.5wt.%, and the content of the antibacterial agent is not more than 0.1wt.%.

9. A method for preparing a nanocomposite emulsion of dihydromyricetin, characterized in that: The steps include: S1: Accurately weigh the material components of dihydromyricetin and hydrophilic core solvent according to weight percentage, first place the components of the hydrophilic core solvent in an appropriate container, stir and mix evenly, and heat the solvent to 50-60° C. in a water bath environment to obtain a hydrophilic core solvent, then pass the solid powder of dihydromyricetin through a 40-mesh sieve, and slowly sieve it into the hydrophilic core solvent being stirred to fully dissolve it, so as to prepare a dihydromyricetin-hydrophilic core solution; S2: Accurately weigh the water-in-oil emulsifier, the co-emulsifier and the oil according to the weight percentage, mix the three materials in a suitable container, and heat them to 50-60° C. in a water bath environment. After they are fully melted, continue to stir them thoroughly to mix the solution evenly, so as to obtain a lipid carrier with a bidirectional hydrophilic structure; S3: adding the dihydromyricetin-hydrophilic core solution prepared in step S1 to the lipid carrier solution with a bidirectional hydrophilic structure prepared in step S2 at a rate of 1 drop / s, and magnetically stirring the mixed solution while adding, and continuing to magnetically stir for 30 minutes after the addition is completed, and then ultrasonically treating the mixed solution to obtain a water-in-oil nanoemulsion; S4: Accurately weigh the materials of the external aqueous phase according to the weight percentage, add the water-in-oil emulsifier, calcium disodium ethylenediaminetetraacetic acid, vitamin C and antibacterial agent to water, heat to 50-60° C., and stir thoroughly to dissolve to obtain the external aqueous phase; S5: stirring the water-in-oil nanoemulsion prepared in step S3, and slowly adding the external water phase prepared in step S4 while stirring, and performing ultrasonic treatment again, to finally prepare a dihydromyricetin nanocomposite emulsion; The ultrasonic treatment in step S3 and step S5 is as follows: in an ice bath, ultrasonic treatment is performed for 5 minutes each time, with an interval of 2 minutes each time, and repeated 3 times, the ultrasonic power is 500W, and the ultrasonic amplitude is 80%; The ultrasonic treatment in step S3 and step S5 can also be replaced by a homogenization treatment, wherein the mixed solution is placed in a homogenizer for homogenization, the power of the homogenizer is 200W, the temperature is controlled at 50-60°C, 2min / time, 3min interval each time, and repeated 6 times.

10. Use of a nanocomposite emulsion of dihydromyricetin in medicines, health products or health drinks, characterized in that: The medicine includes one or more of the medicines for anti-oxidation, anti-cancer, anti-inflammatory, anti-microbial, liver protection and hangover relief.

Images